Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (4)
Type
Type
Guidance (294)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (8)
Health technology evaluations (19)
HealthTech guidance (10)
Highly specialised technologies guidance (4)
Interventional procedures guidance (12)
Medical technologies guidance (9)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (294)
Apply filters
Showing 191 to 200 of 294
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
`Remove $Guidance programme: Technology appraisal guidance filter`
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]
Technology appraisal guidance
TBC
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]
Technology appraisal guidance
20 April 2026
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]
Technology appraisal guidance
18 November 2026
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]
Technology appraisal guidance
10 February 2027
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Technology appraisal guidance
TBC
Previous page
1
…
18
19
Current page
20
21
22
…
30
Page
20
of
30
Next page
Results per page
10
25
50
All
Back to top